US$ 23.83
clinical trials bpc 157 human BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 clinical trials dosage humans
Description
(2025) 6:e70168-e70168

10.1002/hep.26319 Hepatology

The results showed no toxicities or serious adverse events.[ref] Synthetic thymosin beta 4: A phase I safety trial using synthetic thymosin beta 4 at doses from 42 to 1260 mg for 14 days showed no toxicity or serious adverse events.[ref] Human clinical trials for specific conditions: Venous ulcers: Wounds that dont heal, such as venous ulcers, are a significant problem in older patients with limited mobility
How to Use: Administration: For intramuscular (I M.) or intravenous (I V.) injection

F.HongM

Nat Rev Gastroenterol Hepatol 18: 571587, 2021
